( Health Times reporter Qiu Yue) A Health Times reporter reviewed the "Announcement on Carrying out the Fourth Batch of Inter-Provincial Alliance Drug Centralized Procurement in Eight Provinces and Two Regions" issued by the Liaoning Provincial Centralized Procurement Network for Drugs and Medical Consumables and found that , Among the 18 varieties included in the centralized procurement, 11 are non-medical insurance varieties, including monosialotetrahexosylganglioside sodium, thymopentin, creatine phosphate sodium, alprostadil , etc. Multiple key monitoring varieties.
It is rare for so many key monitoring varieties to appear in the alliance’s centralized procurement. Why focus on monitoring and centralized procurement at the same time?
Shi Luwen, director of the International Research Center for Pharmaceutical Management at Peking University, said in an interview with a reporter from the Health Times on July 14 that “focuses on monitoring and centralized procurement of drugs, and there is no conflict between the two. Generally, the drugs under key monitoring are clinical Using a relatively large number of drugs, the main purpose of centralized purchasing of these drugs is to exchange volume for price, make drug costs more reasonable, and reduce the burden on patients. "
In 2019, the National Health Commission issued the "About the Issuance of the First Batch of National Drugs. "Notice on Focusing on Monitoring the Rational Use of Drugs Catalogue (Chemical Drugs and Biological Products)", in which gangliosides, creatine phosphate sodium, alprostadil, and thymopentin all appear in the catalog. The notice pointed out that all medical institutions should establish a drug management system that focuses on monitoring the rational use of drugs and strengthen the full management of the clinical application of drugs in the catalog. Further standardize the prescribing behavior of doctors, formulate medication guidelines or technical specifications for the drugs included in the catalog, and clearly stipulate the conditions and principles for clinical application.
In 2021, the National Health and Health Commission also formulated the "Working Procedures for Adjustment of the National Key Monitoring and Rational Use Drug Catalog", which pointed out that drugs included in the catalog management should have more problems with unreasonable clinical use, abnormally high usage amounts, and impact on the rational use of drugs. Larger chemicals and biologicals.
Mi Neiwang data shows that the annual sales of gangliosides in 2015 and 2016 reached 6 billion yuan, and the market size in 2018 was still 5.623 billion. After 2019, the market size has declined, but it is still as high as 3.787 billion. Yuan. In addition, the sales scale of thymopentin has also shown a fluctuating trend in recent years, falling from 3.59 billion yuan in 2013 to 1.09 billion yuan in 2020.
Kang Zhen, deputy director of the National Licensed Pharmacist Development Research Center of China Pharmaceutical University, told a Health Times reporter that the drugs included in the national key monitoring of rational drug use themselves still have certain clinical needs and efficacy, otherwise they would not be used in such large amounts. It is for this reason that centralized procurement of these drugs is necessary. However, in the past, these drugs may have had problems such as being used too widely, being used off-label, and may even be suspected of abuse. Therefore, for reasons such as standardizing clinical use and protecting medical insurance funds, it is necessary to use these drugs rationally. Monitor and manage.
focuses on monitoring the centralized procurement of drugs. How to supervise the rational use of drugs?
Historical records believe that the rationality of drug use has nothing to do with whether the drug is subject to centralized procurement. Instead, a specialized team of professionals should be formed to take responsibility for rational drug use and care, and this professional person is the pharmacist. should By decomposing the responsibility for caring for rational drug use into pharmacists' daily work, the risk of irrational drug use can be reduced on a regular and sustainable basis.
According to Kang Zhen, pharmacists’ management of rational drug use should be divided into three stages. The first stage is the prospective rational drug use evaluation before medication, that is, prescription review; the second stage is the immediate rational drug use evaluation, that is, pharmaceutical monitoring or Process management of drug treatment; the third stage is retrospective rational drug use evaluation, which is prescription review. "Among them, the immediate and rational drug use evaluation is the most important and needed part, but there is still a lot of room for improvement in our country, and it is the focus of the future development of clinical pharmacy ."
Kang Zhen pointed out, "The frequent adverse reactions of are one of the problems often encountered in the clinical use of key monitoring drugs. Pharmacists may not be as good as doctors in terms of medical knowledge, but their depth of knowledge and understanding of drugs, especially Pharmacists should be more sensitive to possible adverse reactions than doctors, so pharmacists should be involved in the entire clinical drug treatment process and given a certain say in medication use, so that they can complement each other and play their respective roles. Advantage. Now, most of our pharmacists are only responsible for non-clinical work related to drugs, including pharmacists in social pharmacies. If this continues, their original abilities will slowly shrink. "
" Doctors, nurses, pharmacists are all very important professionals who protect people's lives and health. There must be reasonable and sustainable market incentives so that people will be willing to learn these majors and engage in these professional jobs. Talents Only through team building can sustainable development be achieved. "Historical records indicate.
